Folate-targeted immunotherapies: Passive and active strategies for cancer

Batoul Farran, Eluri Pavitra, Prameswari Kasa, Sujatha Peela, Ganji Seeta Rama Raju, Ganji Purnachandra Nagaraju

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.

Original languageEnglish (US)
Pages (from-to)45-52
Number of pages8
JournalCytokine and Growth Factor Reviews
StatePublished - Feb 2019
Externally publishedYes


  • Folate receptor
  • Immune therapy
  • Solid cancers
  • Targeted therapy
  • Vaccines

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Folate-targeted immunotherapies: Passive and active strategies for cancer'. Together they form a unique fingerprint.

Cite this